Pzena Investment Management LLC Raises Stake in Envista Holdings Corporation $NVST

Pzena Investment Management LLC increased its stake in Envista Holdings Corporation (NYSE:NVST) by 7.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 2,459,082 shares of the company’s stock after buying an additional 164,825 shares during the quarter. Pzena Investment Management LLC owned 1.45% of Envista worth $48,050,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. UMB Bank n.a. lifted its holdings in Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock valued at $36,000 after purchasing an additional 1,428 shares during the last quarter. Parallel Advisors LLC lifted its holdings in Envista by 100.1% during the second quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock valued at $55,000 after purchasing an additional 1,397 shares during the last quarter. FourThought Financial Partners LLC purchased a new stake in Envista during the first quarter valued at about $180,000. Vestcor Inc purchased a new stake in Envista during the first quarter valued at about $211,000. Finally, Pallas Capital Advisors LLC purchased a new stake in Envista during the second quarter valued at about $300,000.

Envista Trading Down 5.4%

Shares of Envista stock opened at $19.10 on Monday. Envista Holdings Corporation has a 12-month low of $14.22 and a 12-month high of $23.00. The company has a market cap of $3.17 billion, a price-to-earnings ratio of 59.69, a PEG ratio of 1.02 and a beta of 1.01. The company has a current ratio of 2.44, a quick ratio of 2.08 and a debt-to-equity ratio of 0.46. The company’s 50-day moving average price is $20.71 and its 200-day moving average price is $18.98.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. The firm had revenue of $682.10 million for the quarter, compared to the consensus estimate of $638.21 million. Envista had a net margin of 2.11% and a return on equity of 4.84%. The company’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.11 earnings per share. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. On average, equities analysts expect that Envista Holdings Corporation will post 1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on NVST. Wall Street Zen downgraded shares of Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 30th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Envista in a report on Wednesday, October 8th. Evercore ISI set a $25.00 price objective on shares of Envista in a report on Wednesday. Piper Sandler upped their price objective on shares of Envista from $17.00 to $19.00 and gave the company a “neutral” rating in a report on Friday, August 1st. Finally, Morgan Stanley increased their price target on shares of Envista from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, ten have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $21.08.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.